Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer

Petrović, Marina; Baskić, Dejan; Banković, Dragić; Ilic, Nevenka

doi:10.3109/1354750x.2011.560281

Cited by 29 publications

(19 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although previous studies showed controversial results for NE feature, or NE differentiation, as predicator for prognosis of clinical therapy [29, 30], our results present here revealed significant prognostic values of NE feature for NSCLC patients. These results suggest potential clinical impacts for NE feature as a diagnostic tool for NSCLC and an independent predictor for prognosis of NSCLC patients, and may also provide essential insights for optimization of clinical treatments for NSCLC patients.…”

Section: Discussionsupporting

confidence: 41%

Correlation of neuroendocrine features with prognosis of non-small cell lung cancer

et al. 2016

View full text Add to dashboard Cite

The improvement in histological diagnostic tools, including neuroendocrine markers by immunohistochemistry (IHC), has led to increased recognition of non-small cell lung cancer (NSCLC) with neuroendocrine (NE) feature. However, little is known regarding the prevalence and clinical implications of NE feature in patients with NSCLC. In this study, we performed IHC in a tissue microarray containing 451 Chinese NSCLC cases, and analyzed correlation of the expression of neuroendocrine marker with pathological and clinical features of NSCLC. The result showed that NE feature in NSCLC was detectable in almost 30% of studied patients, and tumors with NE feature were significantly correlated with pathological classification, clinical stages and cell differentiation of NSCLC. Our data also revealed that NE feature indicated worse overall survival and disease free survival. Compared with mutant p53, NE markers showed more significance as for prognostic evaluation. Multi-factor COX analysis further suggested a potential clinical impact for NE feature as an independent indicator of poor prognosis for NSCLC patients.

show abstract

Section: Discussionsupporting

confidence: 41%

Correlation of neuroendocrine features with prognosis of non-small cell lung cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Howe and colleagues [7] reported that the presence of immunohistochemically detected NE differentiation in NSCLC was not of prognostic significance. Conversely, among approximately 116 patients with stage III/IV non-small cell lung carcinoma (NSCLC), the chemotherapeutic response to paclitaxel and cisplatin was significantly better in the NSCLC patients with NE differentiation [8]. They showed that the percentage of NE-positive tumor cells was an independent prognostic factor associated with a favorable outcome.…”

Section: Discussionmentioning

confidence: 99%

Combined large cell neuroendocrine carcinoma with giant cell carcinoma of the lungs: a case report

et al. 2013

View full text Add to dashboard Cite

Combined large cell neuroendocrine carcinoma of the lungs (combined LCNEC) with giant cell carcinoma is extremely rare. A 65-year-old man was found to have an abnormal shadow in his left lung field. Computed tomography revealed a solid, round mass measuring 2.8 × 2.2 cm that was located in the left S9. The patient underwent left lower lobectomy and mediastinal lymph node dissection. Histopathological examination revealed an LCNEC, combined with giant cell carcinoma. The patient received by S-1 (TS-1, an oral fluoropyrimidine) chemotherapy, and he has been disease-free for over 8 months. Combined LCNEC with giant cell carcinoma is an extremely rare tumor with high malignant potential, and thus, multidisciplinary therapy and close follow-up are advised.

show abstract

“…None of them presented expression of chromogranin A, while expression of synaptophysin was confirmed in 15% of cases. Petrovic et al [29] found expression of neuron-specific enolase in 22.4%, chromogranin A in 15.5%, and synaptophisin in 14.8% of tumor cells from locally advanced and advanced NSCLC patients. In their study, the response to chemotherapy was significantly better in patients with NSCLC with neuroendocrine differentiation.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Synaptophysin and Chromogranin A Expression in Patients Receiving Palliative Chemotherapy for Advanced Non-Small-Cell Lung Cancer

Kowalski

Krzakowski²,

Jaśkiewicz³

et al. 2012

Respiration

View full text Add to dashboard Cite

Background: Chemotherapy is the principal treatment method for patients with advanced non-small-cell lung cancer (NSCLC). Treatment with platinum-based and novel chemotherapeutic regimens, compared to monotherapy, slightly increases the response rates to 20-40%. The predictive and prognostic values of molecular factors are highly variable; however, data on clinical-demographic factors are still burdened by significant limitations. Objectives: The aim of this study was to assess the prognostic value of synaptophysin and chromogranin A protein expression in patients receiving palliative chemotherapy for advanced NSCLC. Methods: The study population consisted of 23 women and 116 men. The median age was 57.3 years. Expression of synaptophysin and chromogranin was assessed using a two-step model of immunohistochemical staining. Level 0 represented lack of activity, while level 1 represented its expression. Results: Expression of synaptophysin and chromogranin A was observed in 12 (8.6%) and 5 (3.6%) patients, respectively. The risk of death was significantly lower in patients with expression of synaptophysin (p = 0.008) and chromogranin A (p = 0.014). The 12- and 24-month survival rate of patients with synaptophysin expression was 64% (95% CI 0.35-0.93), while for patients without expression it was 46% (95% CI 0.36-0.56) and 16% (95% CI 0.07-0.25), respectively. The 12- and 24-month survival rate of patients with chromogranin expression was 80% (95% CI 0.44-1.00), while for chromogranin A-negative patients it was 47% (95% CI 0.37-0.57) and 19% (95% CI 0.10-0.28), respectively. We did not observe associations between expression of synaptophysin and chromogranin A and the other typical prognostic factors. Conclusions: Expression of synaptophysin and chromogranin A was associated with a longer median overall survival and might have prognostic value. These results should be confirmed in a prospective study.

show abstract

Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer

Abstract: Advanced-stage NSCLC with NE tumor cells are clinically less aggressive tumors. Percentage of NE-differentiated tumor cells identifies patients with favourable therapy response to paclitaxel-cisplatin.

Cited by 29 publications

References 46 publications

Correlation of neuroendocrine features with prognosis of non-small cell lung cancer

Correlation of neuroendocrine features with prognosis of non-small cell lung cancer

Combined large cell neuroendocrine carcinoma with giant cell carcinoma of the lungs: a case report

Prognostic Value of Synaptophysin and Chromogranin A Expression in Patients Receiving Palliative Chemotherapy for Advanced Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About